Intro
This post is based on the company’s official 10-K filing and investor relations (IR) materials. It summarizes only objective facts and the logical implications that directly follow from them. Personal opinions and forecasts have been minimized. The goal is to help readers understand and interpret the materials more easily.
Table of Contents
👉 1. Business Overview
👉 2. Financial Highlights
👉 3. Valuation
👉 4. Risk
👉 5. MD&A (Management’s Discussion and Analysis)
👉 6. Summary
1. Business Overview 💼
Eli Lilly and Company is one of the world’s largest pharmaceutical companies, focused on discovering, developing, manufacturing, and selling medicines for major diseases such as diabetes, obesity, cancer, immunology, and neuroscience disorders.
Founded in 1876, the company has grown into a global healthcare leader with operations in more than 100 countries. In recent years, Eli Lilly has become one of the most closely watched pharmaceutical stocks in the U.S. market due to the explosive growth of its obesity and diabetes treatments.
Key products include:
- Mounjaro — a diabetes treatment that also became highly popular for weight loss.
- Zepbound — Lilly’s obesity-focused weight management drug.
- Trulicity — a long-established diabetes medication.
- Verzenio — a breast cancer treatment.
- Taltz — an immunology drug used for psoriasis and related conditions.
- Kisunla — a newer Alzheimer’s treatment targeting early-stage disease progression.
🚀 Why Investors Are Paying Attention
Eli Lilly became one of the biggest winners of the global obesity drug boom. Demand for obesity and diabetes treatments increased rapidly across the U.S. and international markets, helping the company achieve extremely strong revenue growth.
The company’s obesity platform is especially important because obesity is connected to multiple chronic diseases, including:
- Type 2 diabetes
- Heart disease
- Sleep apnea
- Kidney disease
- High blood pressure
This gives Eli Lilly exposure to a very large long-term healthcare market rather than a single niche category.
“The obesity treatment market could become one of the largest pharmaceutical opportunities in modern healthcare.”
🧪 Strong Research & Development Focus
One of Eli Lilly’s biggest competitive strengths is its aggressive investment in R&D (Research and Development), which means spending money to create future medicines and improve existing treatments.
The company spends billions of dollars annually on:
- Clinical trials
- Drug discovery
- Biotechnology research
- Manufacturing expansion
- Next-generation obesity and diabetes treatments
For pharmaceutical companies, R&D is critical because patents eventually expire. New medicines must continuously replace older products to maintain long-term growth.
🏭 Manufacturing Expansion
Eli Lilly has also been heavily expanding manufacturing capacity in response to strong demand for obesity drugs.
Manufacturing capacity refers to how much medicine a company can physically produce. This became a major issue because demand for weight-loss drugs grew faster than supply across the pharmaceutical industry.
The company announced large investments in:
- New U.S. manufacturing facilities
- Active pharmaceutical ingredient production
- Injection-device manufacturing
- Global supply-chain expansion
These investments are intended to support future revenue growth while reducing supply shortages.
🌍 Global Business Structure
Eli Lilly operates as a global pharmaceutical business with revenue coming from:
- The United States
- Europe
- Asia
- Latin America
- Other international markets
However, the U.S. market remains the company’s largest source of revenue and profit due to higher drug pricing and strong healthcare spending.
⚠️ Important Risks Investors Should Understand
Despite strong growth, pharmaceutical companies face several major risks:
- Patent expiration risk — competitors can launch generic or biosimilar drugs after patents expire.
- Regulatory risk — drug approvals depend on FDA and international regulators.
- Pricing pressure — governments and insurers may push for lower drug prices.
- Clinical trial risk — new medicines can fail during testing.
- Manufacturing risk — supply shortages can limit sales growth.
Because of these risks, pharmaceutical investing can sometimes be volatile even for large companies.
📊 Business Model Explained Simply
Eli Lilly’s business model is relatively straightforward:
- Create or acquire promising medicines.
- Obtain patent protection and regulatory approval.
- Sell high-demand treatments globally.
- Use profits to fund future drug development.
- Repeat the cycle with new medicines.
The company’s recent success has largely been driven by the rapid adoption of obesity and diabetes treatments, but long-term performance will also depend on whether Lilly can continue producing successful new drugs over the next decade.
🧠 Plain English
Eli Lilly is basically a company that makes high-demand medicines for major diseases. Right now, its biggest growth engine is obesity and diabetes drugs.
The company earns huge profits from successful medicines, then reinvests those profits into developing future treatments. Investors like Lilly because its newest drugs are growing extremely fast, but the company still faces risks like competition, regulation, and patent expiration.
2. Financial Highlights 📊
Income Statement Summary
| (Unit: $m, EPS in $) | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue | 34,124 | 45,043 | 65,179 |
| Cost of Goods Sold | 7,082 | 8,418 | 11,052 |
| Gross Profit | 27,042 | 36,625 | 54,127 |
| SG&A | 7,404 | 8,594 | 11,094 |
| Operating Income | 6,457 | 12,899 | 26,302 |
| Non-Operating Income/Expense | 97 | (219) | (571) |
| Interest Income/Expense | — | — | — |
| Income Before Tax | 6,554 | 12,680 | 25,731 |
| Income Tax | 1,314 | 2,090 | 5,091 |
| Net Income | 5,240 | 10,590 | 20,640 |
| EPS | 5.8 | 11.7 | 23.0 |
Plain English: Eli Lilly’s income statement shows a major step-up in scale. Revenue increased from $34,124m in FY2023 to $65,179m in FY2025, while operating income rose much faster, from $6,457m to $26,302m. This means the company was not only selling more, but also converting a much larger share of those sales into operating profit. Net income nearly quadrupled over the three-year period, and diluted EPS increased from $5.8 to $23.0.
Key Financial Ratios
| Ratio | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| ROE (%) | 48.2% | 74.2% | 77.8% |
| ROA (%) | 8.2% | 13.5% | 18.4% |
| ROTC (%) | 17.9% | 26.9% | 38.1% |
| ROIC (%) | 15.5% | 24.1% | 34.2% |
| Gross Margin (%) | 79.2% | 81.3% | 83.0% |
| Operating Margin (%) | 18.9% | 28.6% | 40.4% |
| Pretax Margin (%) | 19.2% | 28.2% | 39.5% |
| Net Margin (%) | 15.4% | 23.5% | 31.7% |
| Debt-to-Equity Ratio (D/E) (%) | 232.2% | 235.7% | 160.2% |
| Net Debt / EBITDA (x) | 2.8x | 2.1x | 1.2x |
| Interest Coverage Ratio (x) | — | — | — |
| Current Ratio (%) | 94.3% | 115.4% | 157.9% |
| Quick Ratio (%) | 51.9% | 58.3% | 77.8% |
| Fixed Asset to Long-term Capital Ratio (%) | 44.2% | 40.0% | 36.6% |
Plain English: The ratio table shows a sharp improvement in profitability and capital efficiency. Gross margin rose to 83.0%, operating margin reached 40.4%, and ROIC improved to 34.2% in FY2025. For beginners, ROIC means how efficiently a company turns invested capital into operating profit after tax. Eli Lilly also improved its leverage profile: Net Debt / EBITDA fell from 2.8x in FY2023 to 1.2x in FY2025, meaning earnings power grew faster than net debt.
Balance Sheet Summary Template
| (Unit: $m) | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Assets | |||
| Cash & Equivalents | 2,819 | 3,268 | 7,268 |
| Accounts Receivable | 9,091 | 11,006 | 17,760 |
| Inventory | 5,773 | 7,589 | 13,744 |
| Current Assets | 25,727 | 32,740 | 55,629 |
| Property, Plant & Equipment | 12,914 | 17,102 | 24,675 |
| Intangible Assets | 6,907 | 6,166 | 6,521 |
| Non-current Assets | 38,279 | 45,975 | 56,847 |
| Total Assets | 64,006 | 78,715 | 112,476 |
| Liabilities | |||
| Short-term Debt | 6,905 | 5,117 | 1,635 |
| Accounts Payable | 2,599 | 3,229 | 5,379 |
| Current Liabilities | 27,293 | 28,376 | 35,228 |
| Long-term Debt | 18,321 | 28,527 | 40,868 |
| Non-current Liabilities | 25,849 | 36,067 | 50,713 |
| Total Liabilities | 53,142 | 64,443 | 85,941 |
| Equity | |||
| Common Equity | 10,864 | 14,272 | 26,535 |
| Total Liabilities + Equity | 64,006 | 78,715 | 112,476 |
Plain English: Eli Lilly’s balance sheet expanded significantly. Total assets increased from $64,006m in FY2023 to $112,476m in FY2025. The biggest structural changes were higher cash, accounts receivable, inventory, and property, plant and equipment. This reflects a company scaling up rapidly, especially through manufacturing and supply-chain investment. Debt also increased, but equity grew even faster in FY2025, helping the Debt-to-Equity ratio improve from 235.7% in FY2024 to 160.2% in FY2025.
Cash Flow Statement Summary Template
| (Unit: $m) | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Cash Flow from Operating Activities | 4,240 | 8,818 | 16,813 |
| Cash Flow from Investing Activities | (7,153) | (9,302) | (10,972) |
| Cash Flow from Financing Activities | 3,496 | 1,230 | (2,213) |
| Net Change in Cash | 752 | 449 | 4,000 |
| Beginning Cash Balance | 2,067 | 2,819 | 3,268 |
| Ending Cash Balance | 2,819 | 3,268 | 7,268 |
Plain English: Cash flow improved strongly in FY2025. Operating cash flow increased to $16,813m, almost double the FY2024 level. At the same time, investing cash flow remained heavily negative because Eli Lilly continued spending on property, equipment, acquisitions, and in-process research and development. Financing cash flow turned negative in FY2025 as the company paid dividends, repurchased shares, reduced short-term borrowings, and still issued long-term debt. The ending cash balance rose to $7,268m, giving the company more financial flexibility.
Beginner Takeaways
- Revenue growth was very strong: Eli Lilly’s revenue increased from $34,124m in FY2023 to $65,179m in FY2025, mainly reflecting a much larger business scale.
- Profitability improved sharply: Operating margin rose from 18.9% to 40.4%, showing that profit grew much faster than sales.
- Capital efficiency strengthened: ROIC improved to 34.2% in FY2025, meaning the company generated much higher after-tax operating profit from its invested capital base.
- The balance sheet became larger but also stronger: Debt increased, but equity and cash also rose significantly, and Net Debt / EBITDA improved to 1.2x.
- Cash generation became a key strength: Operating cash flow reached $16,813m in FY2025, supporting dividends, share repurchases, R&D investment, and manufacturing expansion.
3. Valuation 📈
Here are the valuation ratios. These numbers don’t tell you by themselves if the stock is cheap or expensive. Investors typically compare them with peers, the broader market, or with their own view of intrinsic value (DCF). It’s up to each investor to judge whether these multiples signal undervaluation or overvaluation.
Valuation Summary
| Metric | Value | What It Means |
|---|---|---|
| Market Capitalization | $845.77B | The total market value of Eli Lilly’s equity. |
| Share Price | $1,021.41 | The market price per share used for this valuation snapshot. |
| P/E Ratio | 44.5x | Price divided by FY2025 diluted EPS. A higher P/E usually means investors are paying more for each dollar of earnings. |
| Forward P/E Ratio | 26.3x | Price divided by expected future earnings. This can be lower than trailing P/E when investors expect earnings to grow. |
| P/B Ratio | 31.9x | Market capitalization divided by total equity. This is high, which often reflects strong profitability expectations rather than asset-heavy valuation. |
| P/S Ratio | 13.0x | Market capitalization divided by FY2025 revenue. This shows how much investors are paying for each dollar of sales. |
| EV/EBITDA | 31.1x | Enterprise value divided by EBITDA. This compares the value of the whole business with operating cash-earnings power before depreciation and amortization. |
| Dividend Yield | 0.6% | Annual dividends per share divided by the share price. Eli Lilly is not mainly valued as a high-yield dividend stock. |
| FCF Yield | 1.1% | Free cash flow divided by market capitalization. This shows how much free cash flow the company generates relative to its market value. |
💡 Plain English Recap
Eli Lilly trades at a premium valuation based on most standard metrics. Its P/E ratio of 44.5x, P/S ratio of 13.0x, and EV/EBITDA of 31.1x show that investors are assigning a high value to the company’s future growth potential.
The Forward P/E of 26.3x is lower than the trailing P/E, which suggests that the market expects earnings to keep rising. For beginner investors, this means Eli Lilly’s valuation depends heavily on whether the company can continue growing earnings from obesity, diabetes, and other major pharmaceutical products.
The Dividend Yield of 0.6% and FCF Yield of 1.1% are relatively low, so the stock is not mainly priced as an income investment. Instead, the market appears to be valuing Eli Lilly primarily as a high-growth, high-quality pharmaceutical company.
1. Forward P/E is shown as a consensus estimate (average from major financial data providers) for reference.
2. Date of preparation: 2026-05-19
4. Risk ⚠️
Editorial Note:
In order to enhance readability, we have omitted broad, market-wide risks that generally affect all companies. The following discussion is focused solely on the risks that are specific to this company and the industry in which it operates.
💉 Dependence on Obesity and Diabetes Drugs
A growing portion of Eli Lilly’s revenue and investor expectations is tied to the long-term success of its obesity and diabetes treatments, including Mounjaro and Zepbound.
- Demand growth may slow over time.
- Competing drugs from other pharmaceutical companies may gain market share.
- Insurance reimbursement policies could change.
- Pricing pressure may increase as the market matures.
- Supply shortages could limit revenue growth.
Plain English: Eli Lilly’s recent growth depends heavily on a small number of blockbuster obesity and diabetes drugs. If demand weakens or competition increases, financial performance could be affected.
🧪 Clinical Trial and Drug Development Risk
Pharmaceutical companies depend on successful clinical trials and regulatory approvals to develop future medicines. Eli Lilly continues investing heavily in research and development across obesity, oncology, immunology, neuroscience, and other therapeutic areas.
- Drug candidates may fail during clinical testing.
- Safety concerns or side effects may emerge.
- Regulators may require additional studies.
- Approval timelines may be delayed.
- Large R&D spending does not guarantee commercial success.
The company also faces uncertainty regarding future pipeline products and whether new medicines will achieve meaningful market adoption after approval.
Plain English: Drug development is expensive and uncertain. Even promising medicines can fail before reaching the market.
🏛️ Regulatory and Drug Pricing Pressure
Eli Lilly operates in a highly regulated industry. Government agencies such as the FDA in the United States and international health authorities closely monitor drug approvals, manufacturing standards, marketing practices, and product safety.
- Regulatory decisions may delay or limit product launches.
- Drug pricing negotiations could reduce profitability.
- Healthcare policy changes may affect reimbursement rates.
- Government programs may seek lower pharmaceutical costs.
The pharmaceutical industry also faces ongoing political and public scrutiny regarding the affordability of medicines, particularly high-demand treatments.
Plain English: Governments and regulators can influence how much pharmaceutical companies are allowed to charge for medicines.
🏭 Manufacturing and Supply Chain Risk
Eli Lilly has been expanding manufacturing capacity rapidly in response to strong demand for obesity and diabetes drugs. Pharmaceutical manufacturing is complex and highly regulated.
- Manufacturing disruptions could reduce product supply.
- Supply chain interruptions may delay production.
- Quality-control problems could lead to regulatory action.
- Rapid expansion projects may face delays or cost overruns.
The company relies on global suppliers and manufacturing facilities for active pharmaceutical ingredients, injection devices, and other production components.
Plain English: If Eli Lilly cannot manufacture enough products efficiently, it may lose sales opportunities even when demand remains strong.
🧬 Patent Expiration and Competition Risk
Pharmaceutical companies rely heavily on patent protection to maintain exclusivity for their medicines. After patents expire, generic or biosimilar competitors may enter the market.
- Competitors may introduce lower-cost alternatives.
- Revenue from older drugs may decline after exclusivity ends.
- Patent litigation may increase legal expenses.
- Competing obesity and diabetes treatments may pressure pricing and market share.
Competition remains intense across multiple therapeutic areas, including obesity, diabetes, cancer, and immunology.
Plain English: Successful drugs eventually face competition, and that can reduce future sales and profit margins.
⚖️ Legal and Product Liability Risk
As a large pharmaceutical company, Eli Lilly faces ongoing legal and compliance risks related to product safety, marketing practices, intellectual property, and healthcare regulations.
- Product liability lawsuits may arise if patients experience adverse effects.
- Patent disputes may create litigation costs.
- Regulatory investigations may result in fines or penalties.
- Advertising and promotional practices are closely regulated.
Large pharmaceutical companies can face substantial legal expenses even when products remain commercially successful.
Plain English: Drug companies can face lawsuits, regulatory investigations, and legal disputes that may increase costs or damage reputation.
🧠 Alzheimer’s and Neuroscience Uncertainty
Eli Lilly continues investing in Alzheimer’s disease and neuroscience treatments, including newer products such as Kisunla. Neurology-related drug development carries unusually high scientific and regulatory uncertainty.
- Clinical outcomes may remain difficult to predict.
- Long-term efficacy and safety data may evolve over time.
- Commercial adoption could depend on physician confidence and reimbursement support.
Plain English: Alzheimer’s treatments are scientifically challenging, and future commercial success is still uncertain.
📝 Risk Summary
Eli Lilly’s key risks are mainly tied to obesity and diabetes drug concentration, clinical trial uncertainty, regulatory and pricing pressure, manufacturing capacity, patent protection, and legal or product liability exposure.
For beginner investors, the main point is simple: Eli Lilly has a powerful growth engine, but that growth depends on continued drug demand, successful product execution, reliable manufacturing, and protection from competition.
5. MD&A (Management’s Discussion and Analysis) 🧭
🚀 Strong Revenue Growth Driven by Obesity and Diabetes Medicines
Management highlighted that FY2025 revenue growth was primarily driven by strong demand for obesity and diabetes products, especially Mounjaro and Zepbound.
- Higher sales volume contributed significantly to revenue expansion.
- New product launches supported growth across major markets.
- Demand for incretin-based medicines remained strong.
- International sales also increased as product availability expanded.
Management noted that obesity and diabetes products became a major contributor to the company’s overall business performance during FY2025.
Plain English: Eli Lilly’s biggest growth engine was continued demand for weight-loss and diabetes treatments.
📈 Margin Expansion and Profitability Improvement
Management reported significant improvement in profitability during FY2025.
- Revenue growth outpaced operating expense growth.
- Gross margin improved due to product mix and operating leverage.
- Operating income increased substantially compared with prior years.
- Net income and earnings per share also rose sharply.
Operating leverage refers to a situation where revenue grows faster than operating costs, allowing profit margins to expand.
Plain English: Eli Lilly became more profitable because sales grew much faster than expenses.
🏭 Manufacturing Expansion and Capacity Investments
Management emphasized continued investment in manufacturing infrastructure to support long-term demand growth.
- The company expanded production capacity for obesity and diabetes medicines.
- Large capital expenditures were directed toward manufacturing facilities.
- Supply-chain investments were intended to improve product availability.
- Management continued focusing on reducing supply constraints.
Capital expenditures are long-term investments in facilities, equipment, and infrastructure used to support future operations.
Plain English: Eli Lilly spent heavily on factories and production systems to manufacture more obesity and diabetes drugs.
🧪 Continued Focus on Research and Development
Management continued emphasizing long-term investment in research and development across multiple therapeutic areas.
- R&D spending increased meaningfully during FY2025.
- The company continued advancing obesity, oncology, immunology, and neuroscience programs.
- Pipeline expansion remained a strategic priority.
- Management continued investing in future product opportunities.
Pipeline refers to medicines currently being researched, tested, or prepared for future commercialization.
Plain English: Eli Lilly continued spending aggressively on future medicines in order to support long-term growth.
💰 Cash Flow and Balance Sheet Developments
Management discussed strong operating cash flow generation during FY2025.
- Operating cash flow increased significantly compared with prior years.
- The company maintained substantial investment activity.
- Cash balances increased during the year.
- Management continued funding dividends, manufacturing expansion, acquisitions, and research programs.
The company also issued additional long-term debt while continuing to invest heavily in future growth initiatives.
Plain English: Eli Lilly generated much more cash from operations and used that cash to invest aggressively in future growth.
🌍 International Growth and Product Expansion
Management highlighted continued international expansion opportunities for key products.
- Demand increased across multiple geographic regions.
- New product launches supported international revenue growth.
- Management continued investing in global commercial infrastructure.
Commercial infrastructure includes sales, distribution, marketing, and operational systems used to support product launches and ongoing business activity.
Plain English: Eli Lilly continued expanding sales of major medicines outside the United States.
📝 MD&A Summary
Management primarily focused on:
- Strong obesity and diabetes drug demand
- Rapid revenue and earnings growth
- Manufacturing expansion
- Heavy R&D investment
- Growing operating cash flow
- Long-term global growth opportunities
The overall tone of management’s discussion reflected strong operational momentum, significant manufacturing investment, and continued emphasis on expanding the company’s long-term product pipeline.
6. Summary ✅
Eli Lilly delivered exceptionally strong growth in FY2025, driven primarily by rising demand for its obesity and diabetes medicines. Revenue, operating income, net income, and cash flow all increased sharply compared with prior years, while profitability margins also improved significantly.
Management continued investing aggressively in manufacturing capacity, research and development, and global expansion in order to support future product demand and long-term pipeline growth.
The company’s financial statements also showed a much larger and stronger business overall, with higher cash balances, expanding operating cash flow, and improving capital efficiency metrics.
At the same time, Eli Lilly remains heavily dependent on continued success in obesity and diabetes treatments, while also facing regulatory, manufacturing, competition, and clinical development risks that are common within the pharmaceutical industry.
For beginner investors, Eli Lilly currently appears to be a rapidly growing pharmaceutical company whose recent performance has been strongly supported by high-demand blockbuster medicines and large-scale investment in future growth opportunities.
📝 Disclaimer
This article is intended for educational purposes only. It does not constitute financial, investment, or legal advice. All investment decisions involve risks, and readers should conduct their own research or consult with a licensed financial advisor.
👉 Eli Lilly and Company (LLY) FY 2025 10-K Key Highlights (Filed 2026) | Explained for Beginners
Originally published on Finvincio